GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Enterprise Value

Arch Biopartners (TSXV:ARCH) Enterprise Value : C$117.25 Mil (As of Apr. 30, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Arch Biopartners's Enterprise Value is C$117.25 Mil. Arch Biopartners's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.57 Mil. Therefore, Arch Biopartners's EV-to-EBIT ratio for today is -74.54.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Arch Biopartners's Enterprise Value is C$117.25 Mil. Arch Biopartners's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-1.57 Mil. Therefore, Arch Biopartners's EV-to-EBITDA ratio for today is -74.54.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Arch Biopartners's Enterprise Value is C$117.25 Mil. Arch Biopartners's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil. Therefore, Arch Biopartners's EV-to-Revenue ratio for today is .


Arch Biopartners Enterprise Value Historical Data

The historical data trend for Arch Biopartners's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Enterprise Value Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.86 86.01 110.67 191.52 72.42

Arch Biopartners Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 179.57 146.86 128.15 72.42 97.61

Competitive Comparison of Arch Biopartners's Enterprise Value

For the Biotechnology subindustry, Arch Biopartners's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Enterprise Value falls into.



Arch Biopartners Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Arch Biopartners's Enterprise Value for the fiscal year that ended in Sep. 2023 is calculated as

Arch Biopartners's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arch Biopartners  (TSXV:ARCH) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Arch Biopartners's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=117.246/-1.573
=-74.54

Arch Biopartners's current Enterprise Value is C$117.25 Mil.
Arch Biopartners's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.57 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Arch Biopartners's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=117.246/-1.573
=-74.54

Arch Biopartners's current Enterprise Value is C$117.25 Mil.
Arch Biopartners's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.57 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Arch Biopartners's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=117.246/0
=

Arch Biopartners's current Enterprise Value is C$117.25 Mil.
Arch Biopartners's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arch Biopartners Enterprise Value Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners (TSXV:ARCH) Business Description

Traded in Other Exchanges
N/A
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.